At the Cantech Investment Conference in Toronto, Robert Galarza, CEO of BLOCKStrain Technology (TSXV:DNAX,OTCQB:BKKSF), spoke with the Investing News Network (INN) about the launch of its cannabis validation testing program and blockchain’s role in the cannabis sector.

BLOCKStrain Technology is a company that developed the first integrated blockchain platform that can track and register intellectual property in the cannabis industry.


In January, the company launched the first-of-its-kind cannabis strain validation program with WeedMD (TSXV:WMD,OTCQX:WDDMF). The strain validation program is a testing and verification process that confirms cannabis strains as purchased.

Considering investing in blockchain?

 
Read your free 2020 blockchain outlook report!
 

Galarza said that the program’s launch was the “culmination of science and technology coming together.”

Further, Galarza said that the industry has to be “cautious” on how soon blockchain is adopted as a keyword and attached to the cannabis space, despite the technology itself being an “important platform.”

He also spoke about the company’s foray into cannabidiol (CBD) market, where it has partnered with AKESO and NXT Water for a bottled beverage.

Below is a transcript of our interview with Reid. The transcript has been edited for clarity and brevity.

INN: On January 15, WeedMD and BLOCKStrain announced a first-of-its-kind cannabis validation testing program. How important is the strain validation program for the industry and the company?

RG: I’ll tackle the industry first, because so goes the industry, so goes our company. We are at the precipice of needing this system in order to build integrity at all within the industry. So it is paramount for companies like ourselves to be able to say, “Okay, if you’re a producer, if you’re producing great product, create a solution that allows you to be able to understand that product, manage that product, and really identify that product”.

So for us, the exciting thing about the program going live is it’s a couple things. It’s a culmination of science and technology coming together in the right way at the right moment. At the end of the day, it’s also being able to go to a … what we believe is a very top level producer, it’ll say, “You know what? You can now take any WeedMD product bought, in the past or in the future and take a sampling of it. If it says it’s Ghost Train Haze, we’ll check to make sure and validate that it is actually Ghost Train Haze in the same genetic way that it was in the beginning. It’s so important because each genetic strain is so different.

Interested in investing in the tech industry?

 
Learn the basics of tech investment in this FREE report!
 

So it was a really big opportunity for us … it’s all about get the tech going, but also being live. And now we’re there, we’re ready for business all across the board, so it’s fantastic.

INN: As you termed it as the first of its kind, were there any hurdles that the team experienced during the process?

RG: Yeah. From a process perspective, it’s been very smooth with WeedMD. They’ve been an incredible partner in the development.

But the most difficult part about the journey when you’re doing any sort of new technology,is getting people to understand where innovation fits in. So, why blockchain, where in the genomics component? How do we utilize the genetics? Can genetics actually be used for validation and QA? Years ago, cannabis genetics wasn’t nearly where it is today, right? It just evolved so rapidly in the last few years. So that was the one thing, just education a little bit. But once we turned that corner, it’s been fantastic.

INN: In the past several months, we have seen more companies enter into the cannabis space embracing blockchain. What’s your take on this? Is this a sign of things to come? Will more companies embrace blockchain in the future?

RG: 2018, in a lot of ways, I think, was a learning process for companies like ourselves, for the cannabis industry [and] for the blockchain industry, especially. What blockchain is, decentralized ledger technologies versus tokenization and cryptocurrencies. I think, where we’re going to meet, where we’re going to intersect, is when we start talking about being able to track records and to validate where integrity becomes an issue.

Considering investing in blockchain?

 
Read your free 2020 blockchain outlook report!
 

Now usually, you know [role of blockchain] falls into the testing side where we live, or sometimes into the supply chain where we also live. But really, at the end of the day, those are the points that the ledger can be very functional and very usable. We have to be very cautious about how quickly we just take that keyword and just say we’re going to attach it to this industry and run with it. The technology itself is the most important platform, the software, that’s what blends it all.

INN: Are there any projects that BLOCKStrain is currently working, or that you can share with us today?

RG: Yeah, so what we’re really excited about is … we just announced our first foray into the CBD market. And it’s a little bit different, because the genetic side of CBD is not really as much of a concern. But with CBD, it’s the source materials … there’s a joke in CBD that it means “Could Be Dishwater,” because there’s not really a lot of integrity.

The source material is going into the bottles. So you’re going to pay $8.99 for a bottle that’s got cannabinoids in it, you want to know if it’s actually got cannabinoids in right level.

What we’ve done is we partnered with a group called Akeso and NXT Water out of LA, so they’re really amazing companies in LA that are doing this functional fitness water. And it’s all with an incredibly high level of CBD, and it’s literally bottled, they’re making this incredible fitness water.

Considering investing in blockchain?

 
Read your free 2020 blockchain outlook report!
 

INN: Why should investors look to BLOCKStrain as a potential investment opportunity?

RG: Good timing. 2018 was a rollercoaster. Anything associated with blockchain, whether we [utilize] crypto currency or not, [it] got caught up in that wave.

Whenever you can jump on a tech company right after they run live with a product, remember how the technology curve is, right? It’s a hockey stick, right? We are hoping that 2019 is the year where we take that pivot up.

And so it’s all about that adoption. Most tech companies, it’s, “Oh, we’re in development … and we’re developing this and we’re partnering with this to develop and design”. Great. We’re live. We’re taking on genetics as we speak. We’re actively moving product to the market today, and that’s a good time to be a part of a software company as we start to onboard and increase our output.

INN: Is there anything you want to add about BLOCKStrain?

RG: No. I mean, again, it’s an exciting year. We’re expanding our horizons globally … so we’re moving into that space step by step. In the meantime, focusing on the needs of our current existing clients, and on boarding our new license of production as well.

Don’t forget to follow us @INN_Technology for real-time news updates!

Securities Disclosure: I, Bala Yogesh, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: BLOCKStrain Technology is a client of the Investing News Network. This article is not paid-for content.

The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in contributed article. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Interested in investing in the tech industry?

 
Learn the basics of tech investment in this FREE report!
 
  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less